Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 28000 shares traded. The stock had previously closed at C$0.04.
Hemostemix Price Performance
The firm has a market cap of C$3.59 million, a P/E ratio of -1.00 and a beta of 0.55. The company’s 50 day simple moving average is C$0.06 and its 200-day simple moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
See Also
- Five stocks we like better than Hemostemix
- Quiet Period Expirations Explained
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Value Stocks You Can Buy Before They Become Big
- Dividend Capture Strategy: What You Need to Know
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.